Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 270 participants.

Also called NCT02551172

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02551172
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02551172. Randomized; double masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
Condition
Hyperlipidemias
Intervention (Drug)
HCP1105
Intervention (Drug)
HGP0816
Intervention (Drug)
Placebo of HCP1105
Intervention (Drug)
Placebo of HGP0816
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct02551172
Content hash
3a21816171d8a9c378495bbdb56ef418b29a23bcbceebd0bfc6863c5e2d7415d